GLAUKOS Corp (GKOS): what the price assumes

Generated: 2026-07-25 · Source: https://boothcheck.com/report/GKOS

Headline

Field	Value
Ticker	GKOS
Company	GLAUKOS Corp
Current price	$153.53/sh
Composition	Glaucoma 83% / Corneal Health 17%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	revenue-multiple
EV / sales paid	17.6x
Steady-state operating margin assumed	28.7%
Must persist for	15.2y

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 11% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.4 years.

Reconcile: at the x-ray's 9.3% required return this reads ~11.4 years; the models below use their own rates.

How unusual the bet is: elevated

Reference	Value
vs own history	+0.46σ
sustained it ~10 years at this level	14%
implied end-window share	0%

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	14.01x	2	expensive
Earnings	—	0	—
Relative	4.04x	2	expensive
Growth	4.26x	2	expensive

Families that call it expensive: Asset, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=6)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$0.00	—	no	Negative/zero FCF — equity value floored at $0
DCF Exit Multiple	Growth	$0.00	—	no	Negative/zero FCF or EBITDA — equity value floored at $0
Relative Valuation	Relative	$38.01	4.04x	yes	P/S fallback (negative EPS): Sector P/S 4.0x × TTM revenue — excluded from consensus
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$11.56	13.28x	yes	Book value floor: BV/sh $11.56, ROE negative
Two-Stage Excess Return	Asset	$10.41	14.75x	yes	Book value with convergence: BV/sh $11.56, ROE converges to ke
Discounted Future Market Cap	Growth	$109.72	1.40x	yes	Rev $0.6B, growth 30% (input: historical growth; tapered), Terminal P/S: 9.6x / 12.0x / 14.4x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair Value	Relative	$0.00	—	no	Negative/zero EPS — earnings-based value floored at $0
Margin Trajectory	Growth	$21.58	7.11x	yes	Margin ramp: -34% → 12% over 7yr, rev growth 30% (input: historical growth; tapered)
Earnings Power Value	Earnings	—	—	no	—
Residual Income	Asset	—	—	no	—
Graham Number	Asset	—	—	no	—
EV/EBITDA Relative	Relative	—	—	no	—
FCF Yield	Earnings	—	—	no	—
SBC-Adj FCF Yield	Earnings	—	—	no	—
Ben Graham Formula	Earnings	—	—	no	—
ROIC-Justified P/B	Asset	—	—	no	—
P/Sales Sector	Relative	$38.01	4.04x	yes	Revenue $0.55B × sector P/S 4.0x
PEG Fair Value	Relative	—	—	no	—
Earnings Yield	Earnings	—	—	no	—
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net debt	$21.6m
Interest coverage	-17.2x
Share count CAGR (dilution)	4.0%
Burning cash	yes

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

Glaukos does not yet earn an operating profit, so traditional valuation models price it on sales, about 14.6 times revenue. They miss what the company is actually building: a glaucoma-implant franchise growing 41% with iDose TR adoption accelerating.

The price implies the business eventually earns a roughly 29% operating margin and grows revenue near its self-funding ceiling for about 14 years. That is a steep bet, and no valuation family currently reaches the price.

The company is still losing money (a $19.8 million GAAP net loss in Q1 2026) but is funded, with $280.5 million in cash and no debt. The bet is that high gross margins near 84% and rapid product adoption convert into the profitability the price assumes.

Bull Case

What the traditional valuation models miss about Glaukos is the gap between a deeply negative current operating margin and the economics of the products actually driving the business. The standard frames see a company losing money and conclude it is wildly overpriced. What they cannot see is that Glaukos is a single-segment ophthalmic medical-technology company (FY2025 10-K, accession 0001193125-26-061944) commercializing high-gross-margin implantable devices for glaucoma, with reported gross margin around 78% and non-GAAP gross margin near 84%. A business with 84% gross margins is not a low-quality enterprise burning cash on a commodity, it is a product company investing the gross profit into a commercial ramp. The losses are a choice about timing, not a verdict on the unit economics.

The product ramp is the part the models cannot price and the numbers are now showing. Q1 2026 net sales jumped 41% on a reported basis to a record $150.6 million, led by U.S. Glaucoma revenue of $93.5 million, up 58% year over year, with the iDose TR sustained-release therapy contributing approximately $54 million. iDose TR is a procedural drug-delivery implant that addresses a large, chronic, underserved glaucoma population, and its rapid adoption is the kind of S-curve that revenue-multiple valuation captures only crudely. The corneal-health business adds a second growth vector, with the Epioxa launch underway. A company growing 41% with an 84% gross margin and two distinct product platforms is building toward the scaled, profitable business the price assumes.

Management's confidence and the balance sheet support the runway. On the strength of the first quarter, Glaukos raised full-year 2026 net sales guidance to $620 million to $635 million, up from $600 million to $620 million. The company ended the quarter with $280.5 million in cash and no debt, meaning it can fund the commercial buildout without raising capital or taking on leverage. Against the medical-device peer set of Procept BioRobotics, AxoGen, Butterfly, AtriCure, and iRhythm, Glaukos is the high-gross-margin glaucoma-and-corneal franchise whose growth and product adoption are the assets the static models structurally undervalue. The losses are real, but they are funding a franchise whose gross economics suggest profitability is a scaling question, not a viability one.

Bear Case

The honest way to frame the bear case is as a disagreement among the valuation methods, and the conservative ones are likely the more reliable read. No valuation family reaches the price. The asset-based frames land lowest and most damningly: simple excess return near $12 and two-stage excess return near $10, against a $131 (June 27, 2026) quote, because the company has little tangible earning power to capitalize. The relative-multiple lens lands near $38, about a quarter of the price. Even the growth-oriented frames disagree, with the margin-trajectory model near $22 and only the discounted-future-market-cap method, the single most generous frame, reaching near the quote at about $110. When the methods scatter this widely and every grounded one says the stock is worth a fraction of its price, the burden of proof sits entirely on the most optimistic projection.

The second problem is the magnitude of the assumption embedded in the price. At about 14.6 times revenue, the valuation implies the business eventually earns a roughly 29% operating margin, an enormous swing from the current negative-36% operating margin, and sustains revenue growth near its self-funding ceiling for about 14 years. History says only about 14% of comparable fast-growers sustain that pace for even ten years. Glaukos is being asked to grow rapidly for well over a decade and to expand from deep losses to a high operating margin, two demanding conditions that both have to hold for the price to be justified. A 41% growth quarter is impressive, but it is one quarter against a 14-year assumption.

The third risk is reimbursement and competition, which the company's own filing flags directly. The 10-K notes that policy actions "by five of the seven MACs, have disrupted traditional customer ordering patterns and may have resulted in certain of our customers' utilization of competitive products, which has reduced U.S. Glaucoma" revenue (accession 0001193125-26-061944). Medicare Administrative Contractor coverage decisions can swing demand for procedural devices overnight, and the glaucoma-device market is competitive, with rivals pursuing the same minimally-invasive surgical and drug-delivery opportunities. The company is still losing money (a $19.8 million GAAP net loss in Q1), so it depends on continued execution and on payers and physicians adopting iDose TR on the trajectory the price assumes. The $280.5 million cash balance removes near-term funding risk, but it does not change the core tension: the grounded valuation methods value Glaukos far below its price, and bridging the gap requires a 14-year, deep-loss-to-high-margin transformation against reimbursement and competitive headwinds.

Valuation

Glaukos is valued on sales rather than profit, because its trailing operating profit sits below the steady-state level the price assumes. At $131.09 the market is paying about 14.6 times revenue, which inverted at a 10.9% cost of capital implies the business eventually earns an operating margin near 29% and grows revenue at its self-funding ceiling for roughly 14 years. Each percentage point of assumed growth moves that implied horizon by about 2.2 years. The priced-in assumption reads as elevated: the near-term growth pace is within what the company has recently delivered, but only about 14% of comparable fast-growers have sustained it for a decade, and the required margin is far above anything Glaukos has earned.

The model X-ray is thin because the company is unprofitable, so the earnings-power family has no applicable methods and the others scatter widely. The asset-based frames land lowest (simple excess return near $12, two-stage excess return near $10), reflecting little tangible earning power to value. The relative-multiple lens lands near $38. The growth family splits, with the margin-trajectory model near $22 and the discounted-future-market-cap frame, the only one that reaches the price, near $110. The blended cross-method anchor sits near $17, a small fraction of the quote. With four families populated and three of them far below the price, the valuation is carried almost entirely by one generous forward projection.

The balance sheet is the reassuring part and removes near-term funding risk. Glaukos ended Q1 with $280.5 million in cash and no debt, enough to fund the commercial ramp without dilution or leverage. The recent results, record net sales up 41%, U.S. Glaucoma up 58%, iDose TR contributing about $54 million, 84% non-GAAP gross margin, and raised full-year guidance, are real and material to the forward thesis. The reasonable conclusion is that Glaukos is a high-gross-margin, fast-growing ophthalmic franchise whose price already assumes it becomes a large, high-operating-margin business over roughly 14 years. The product adoption is genuine and accelerating; the price has already paid for the franchise reaching scale and full profitability.

Catalysts

The Q1 2026 report on April 29 was the most recent catalyst and a strong one. Record net sales rose 41% on a reported basis (39% constant currency) to $150.6 million, led by U.S. Glaucoma revenue of $93.5 million, up 58% year over year, with iDose TR contributing approximately $54 million. GAAP gross margin was about 78% and non-GAAP gross margin near 84%. The company posted a GAAP net loss of $19.8 million, or ($0.34) per share, and raised full-year 2026 net sales guidance to $620 million to $635 million from $600 million to $620 million. The stock gained on the beat and improved outlook. (Sources: StockTitan 8-K and 10-Q summaries; BioSpace press release; Yahoo Finance.)

The product ramps are the catalysts that matter. iDose TR adoption in the U.S. glaucoma franchise is the primary growth driver, and the Epioxa launch is opening the corneal-health vector. The signals to watch are iDose TR uptake and Medicare Administrative Contractor coverage decisions, which the company has flagged as a source of disrupted ordering patterns, the Epioxa launch trajectory, and the pace at which the deep operating losses narrow toward the profitability the price assumes. Because the price embeds a roughly 14-year growth runway and a large margin expansion, each quarter is a referendum on whether the adoption curve and the path to profit are real. (Sources: The Motley Fool Q1 2026 transcript; StockTitan; BioSpace.)

Peer Cohorts (Per Segment, With Filing Citations)

Glaukos (single operating segment) (reported)

• ALC (Alcon Inc.)
• (no filing in the citation store)
• BLCO (Bausch & Lomb Corp)
• (no filing in the citation store)
• PRCT (PROCEPT BioRobotics Corporation)
• (no filing in the citation store)
• ATRC (AtriCure, Inc.)
• (no filing in the citation store)
• AXGN (AXOGEN, INC.)
• (no filing in the citation store)
• PEN (Penumbra, Inc)
• (no filing in the citation store)
• NVCR (NovoCure Limited)
• (no filing in the citation store)
• ESTA (Establishment Labs Holdings Inc.)
• (no filing in the citation store)

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.